Melatonin as a Therapy for Traumatic Brain Injury: A Review of Published Evidence
Open Access
- 22 May 2018
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (5) , 1539
Abstract
Melatonin (MEL) is a hormone that is produced in the brain and is known to bind to MEL-specific receptors on neuronal membranes in several brain regions. MEL’s documented neuroprotective properties, low toxicity, and ability to cross the blood-brain-barrier have led to its evaluation for patients with traumatic brain injury (TBI), a condition for which there are currently no Food and Drug Administration (FDA)-approved therapies. The purpose of this manuscript is to summarize the evidence surrounding the use of melatonin after TBI, as well as identify existing gaps and future directions. To address this aim, a search of the literature was conducted using Pubmed, Google Scholar, and the Cochrane Database. In total, 239 unique articles were screened, and the 22 preclinical studies that met the a priori inclusion/exclusion criteria were summarized, including the study aims, sample (size, groups, species, strain, sex, age/weight), TBI model, therapeutic details (preparation, dose, route, duration), key findings, and conclusions. The evidence from these 22 studies was analyzed to draw comparisons across studies, identify remaining gaps, and suggest future directions. Taken together, the published evidence suggests that MEL has neuroprotective properties via a number of mechanisms with few toxic effects reported. Notably, available evidence is largely based on data from adult male rats and, to a lesser extent, mice. Few studies collected data beyond a few days of the initial injury, necessitating additional longer-term studies. Other future directions include diversification of samples to include female animals, pediatric and geriatric animals, and transgenic strains.Keywords
This publication has 55 references indexed in Scilit:
- EXPRESSION OF CONCERN: Simultaneous modulation of COX‐2, p300, Akt, and Apaf‐1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cellsJournal of Pineal Research, 2012
- The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated ToxicityJournal of Neuroscience, 2011
- Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injuryNeuroscience Letters, 2011
- Sleep disturbance and melatonin levels following traumatic brain injuryNeurology, 2010
- The Antiapoptotic Activity of Melatonin in Neurodegenerative DiseasesCNS Neuroscience & Therapeutics, 2009
- Dual effects of melatonin on oxidative stress after surgical brain injury in ratsJournal of Pineal Research, 2008
- Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in ratsJournal of Pineal Research, 2007
- Influence of dietary melatonin on photoreceptor survival in the rat retina: An ocular toxicity studyExperimental Eye Research, 2007
- The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebratesCellular and Molecular Life Sciences, 1993
- PET and plasma pharmacokinetic studies after bolus intravenous administration of [11C]melatonin in humansInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991